Acadia Pharma (ACAD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $26.22 -0.72%
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: -62.5%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $11.96 million versus the consensus estimate of $9.05 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- Acadia Pharmaceuticals (ACAD) PT Raised to $36 at RBC Capital
- What Delta’s report tells investors in American and United
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
